These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12587356)

  • 21. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.
    Jerrell JM
    Schizophr Bull; 2002; 28(4):589-605. PubMed ID: 12795493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.
    Lucey JV; Libretto SE
    Ir J Med Sci; 2003; 172(4):195-201. PubMed ID: 15029989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
    Leslie DL; Rosenheck R
    J Nerv Ment Dis; 2001 Jun; 189(6):377-83. PubMed ID: 11434638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
    Zhao Z
    Curr Med Res Opin; 2004 Jul; 20(7):1039-48. PubMed ID: 15265249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of atypical antipsychotics in a Veterans Affairs hospital.
    Schwartz TL; Saba M; Hardoby W; Virk S; Masand PS
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1207-10. PubMed ID: 12452548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study.
    Kasper S; Rosillon D; Duchesne I;
    Int Clin Psychopharmacol; 2001 Jul; 16(4):179-87. PubMed ID: 11459331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of cost, dosage and clinical preference for risperidone and olanzapine.
    Rabinowitz J; Lichtenberg P; Kaplan Z
    Schizophr Res; 2000 Dec; 46(2-3):91-6. PubMed ID: 11120420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
    Schooler NR
    J Clin Psychopharmacol; 1998 Apr; 18(2):174-6. PubMed ID: 9555605
    [No Abstract]   [Full Text] [Related]  

  • 32. Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
    Gheuens J; Grebb JA
    J Clin Psychopharmacol; 1998 Apr; 18(2):176-9. PubMed ID: 9555606
    [No Abstract]   [Full Text] [Related]  

  • 33. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
    Kasper S; Hale A; Azorin JM; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 2():II1-II14. PubMed ID: 10603070
    [No Abstract]   [Full Text] [Related]  

  • 34. Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.
    Edell WS; Rupnow MF
    Manag Care Interface; 2003 May; 16(5):64-7. PubMed ID: 12789866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():3-9. PubMed ID: 9766613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health care costs for schizophrenia patients started on olanzapine versus risperidone.
    Russo PA; Smith MW; Namjoshi M
    Am J Health Syst Pharm; 2005 Mar; 62(6):610-5. PubMed ID: 15757882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".
    Clewell JD; Baker RW
    Value Health; 2005; 8(2):175-6. PubMed ID: 15804326
    [No Abstract]   [Full Text] [Related]  

  • 38. Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients.
    Verma S; Orengo CA; Kunik ME; Hale D; Molinari VA
    Int J Geriatr Psychiatry; 2001 Feb; 16(2):223-7. PubMed ID: 11241729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of risperidone and olanzapine on the indications for clozapine.
    Ganguli R; Brar JS
    Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An economic comparison of risperidone and olanzapine use within an integrated managed mental health program.
    Johnsrud M; Crismon ML; Thompson A; Grogg A
    Adm Policy Ment Health; 2006 Mar; 33(2):237-43. PubMed ID: 16237504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.